gdc
PSSGuide_2021

Bladder Cancer

Bladder Cancer
Bladder cancer is the fourth most common cancer type in men, but many new therapies are now being used. Here’s an excellent overview of the risk factors, symptoms, and treatments.
Bladder CancerImmunotherapy
Take a look at the 5 new promising immunotherapies approved by the FDA for bladder cancer after decades of no new treatment options for this type of cancer.
Bladder CancerFDA Approvals, News & Updates
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Bladder CancerFDA Approvals, News & UpdatesUrothelial Cancer
In April 2020, the FDA approved Jelmyto as the first treatment for low-grade upper-tract urothelial cancer, a rare cancer that affects the urinary system.
Bladder Cancer
Interim analysis of the phase 3 JAVELIN Bladder 100 trial showed that maintenance therapy with the PD-L1 inhibitor Bavencio (avelumab) plus best supportive care significantly prolonged survival compared with the current best supportive care alone in patients with advanced urothelial carcinoma, the most common type of bladder cancer, that did not progress (get worse) after treatment with first-line platinum-based chemotherapy.
Bladder Cancer
Here are the drugs and financial support services available to patients receiving treatment for Bladder Cancer.
Bladder CancerImmunotherapyPatient Stories
Michael Morigi shares his very positive experience with immunotherapy in the treatment of his stage III bladder cancer.

Results 1 - 9 of 9

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest